Hims & Hers HealthHIMS +3.76%81 Days Payable is 97.19 as of Mar. 2026, which is 30% above its 10-year median of 75.04. GuruFocus rates HIMS with a GF Score™ of 81/100 and a GF Value™ of $38.70 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Hims & Hers Health ranks better than 52.28% on this metric.
The historical rank and industry rank for Hims & Hers Health's Days Payable or its related term are showing as below:
HIMS'
s Days Payable Range Over the Past 10 Years
Min: 69.54 Med: 75.04 Max: 93.94
Current: 93.94
During the past 7 years, Hims & Hers Health's highest Days Payable was 93.94. The lowest was 69.54. And the median was 75.04.
HIMS's Days Payable is ranked better than 52.28% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs HIMS: 93.94
Hims & Hers Health's Days Payable
increased
from Mar. 2025 (58.78) to Mar. 2026 (97.19).
It may suggest that Hims & Hers Healthdelayed paying its suppliers.
Hims & Hers Health Days Payable Related Terms
Hims & Hers Health Days Payable Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hims & Hers Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hims & Hers Health (HIMS) has a Days Payable of 97.19 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hims & Hers Health and its competitors. This is 30% above median its historical median of 75.04. Over the past decade, Hims & Hers Health's Days Payable has ranged from 69.54 to 93.94. According to the industry distribution chart, Hims & Hers Health ranks #439 out of 920 companies in the Drug Manufacturers industry, placing it in the top 47.7%.
Is Hims & Hers Health's Days Payable too high?
Hims & Hers Health's current Days Payable of 97.19 is 30% above median its 10-year median of 75.04. Over the past 10 years, this metric has ranged from a low of 69.54 to a high of 93.94. The Drug Manufacturers industry median Days Payable is 90.84. Hims & Hers Health's value of 97.19 is 7% above this industry median. Based on the distribution chart, Hims & Hers Health ranks #439 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hims & Hers Health has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's Days Payable compare to LNTH and LQDA?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #439 out of 920 companies for Days Payable. This puts Hims & Hers Health in the upper half of its industry. The industry median Days Payable is 90.84. Hims & Hers Health's value of 97.19 is 7% above this benchmark. Historically, Hims & Hers Health's own Days Payable has ranged from 69.54 to 93.94 over the past decade. While the company's 10-year median is 75.04 vs. the industry median of 90.84, Hims & Hers Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hims & Hers Health's current Days Payable of 97.19 is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current Days Payable is 97.19, which is 30% above median its own 10-year median of 75.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (HIMS) is currently considered Modestly Undervalued. The stock's GF Value™ is $38.70, compared to a current price of $33.94 — trading 12.3% below its estimated fair value. The current Days Payable is 97.19, which is 30% above median its 10-year median of 75.04 and 7% above the Drug Manufacturers industry median of 90.84. Hims & Hers Health's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hims & Hers Health (HIMS), the current Days Payable is 97.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of $33.94 is trading 12.3% below its estimated GF Value™ of $38.70.
GuruFocus considers Hims & Hers Health to be Modestly Undervalued.
Key valuation signals for HIMS:
Days Payable: 97.19 (30% above median its 10-year median of 75.04)
GF Value™: $38.70 vs. price of $33.94 (12.3% below fair value)
Industry Position: 7% above the Drug Manufacturers median (#439 of 920)
No single metric tells the full story. See the HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
81GF Score
Get the complete analysis for HIMS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIMS has been successfully added to your 
